-
Mashup Score: 0
Senthil Damodaran, MD of MD Anderson explains the Phase II study of copanlisib in patients with tumors with PIK3CA mutations (PTEN loss allowed): NCI MATCH EAY131-Z1F Bottom line: NCI-MATCH (EAY131) is a platform study in which patients (pts) with solid tumors, lymphomas, or multiple myeloma are enrolled in targeted therapies based on subsequent genomic interest shifts (NCT02465060). In pts with…
Source: www.oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
The combination of ibrutinib and venetoclax will be tested as frontline therapy in previously untreated patients with mantle cell lymphoma as part of the 3-part phase 3 SYMPATICO trial.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The combination of ibrutinib and venetoclax will be tested as frontline therapy in previously untreated patients with mantle cell lymphoma as part of the 3-part phase 3 SYMPATICO trial. https://t.co/1AqbVMHvO8 #lymphomas
-
-
Mashup Score: 0Lymphoma Treatment Paradigm Refined Over Years, Expert Says on World Lymphoma Awareness Day - 5 year(s) ago
In an interview with Targeted Oncology, Thomas M. Habermann, MD, reflects on the advancements he has observed in the treatment paradigm for lymphomas.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
"The most exciting advances include the continued evolution of team science to further the field," Dr. Habermann said during our interview regarding advances in #lymphomas during #BloodCancerAwarenessMonth. https://t.co/f69uaE5T5j
-
-
Mashup Score: 0
Targeted Oncology was joined by Kami J. Maddocks, MD, for the discussion of a 76-year-old man with relapsed/refractory diffuse large B-cell lymphoma in a recent tweet chat.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
“I think this patient case is the perfect example of where [tafasitamab/lenalidomide] can fit into the treatment landscape,” Dr. Maddocks told us in regard to the patient case she discussed during our recent #TargetedChat tweet chat. https://t.co/QxnJWe2VSE #lymphomas #lymsm
-
-
Mashup Score: 0HIV-Positivity in Classic Hodgkin Lymphoma Shows Comparable Outcomes to Patients Without HIV - 5 year(s) ago
Patients with classic Hodgkin lymphoma and human immunodeficiency virus were found to have similar clinical outcomes compared with patients with cHL and no HIV, according to an analysis presented during the eighth annual virtual meeting of the Society of Hematologic Oncology.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
FROM #SOHO2020: Patients with classic Hodgkin lymphoma and human immunodeficiency virus were found to have similar clinical outcomes compared with patients with cHL and no HIV, according to an analysis. https://t.co/BC0f9JyYkc #lymphomas
-
-
Mashup Score: 0
Targeted Oncology was joined by Kami J. Maddocks, MD, for the discussion of a 76-year-old man with relapsed/refractory diffuse large B-cell lymphoma in a recent tweet chat.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Check out the key takeaways from our recent #TargetedChat tweet chat, which reviewed the case of a patient with relapsed/refractory diffuse large B-cell lymphoma. https://t.co/QxnJWe2VSE #lymsm #lymphomas
-
-
Mashup Score: 4Deciding on Rituximab Versus Obinutuzumab in Follicular Lymphoma - 5 year(s) ago
John M. Burke, MD, discusses treatment with rituximab versus obinutuzumab in patients with advanced stage follicular lymphoma with high tumor burden.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Dr. Burke discusses treatment with rituximab versus obinutuzumab in patients with advanced stage follicular lymphoma with high tumor burden. https://t.co/O4Cgou0hwf #lymsm #lymphomas
-
-
Mashup Score: 3
Abstract. The majority of historical therapies for managing T-cell lymphomas (TCLs) have consisted of T-cell–depleting strategies. Unfortunately, these forms o
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
#OncoAlert Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell #lymphomas | @BloodAdvances | American Society of Hematology #lymsm #ImmunoOnc https://t.co/OyWiMTLKgj
-
-
Mashup Score: 0Gilead's Kite submits FDA approval application for CAR-T in slow-growing lymphomas - MedCity News - 5 year(s) ago
The company said Friday that it had submitted for approval of Yescarta in follicular and marginal zone lymphoma, based on data from the ZUMA-5 study that were presented at the 2020 ASCO meeting in May.
Source: MedCity NewsCategories: General Medicine News, Latest HeadlinesTweet-
Gilead’s Kite submits FDA approval application for CAR-T in slow-growing lymphomas, writes @biotechvisigoth @medcitynews https://t.co/bUMo0XEIy9 #FDA #CART #lymphomas $GILD
-
-
Mashup Score: 0The Cancer News Daily - 5 year(s) ago
The latest in cancer medicine and translational research by Wafik El-Deiry MDPhD
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet-
The latest The Cancer News Daily! https://t.co/fDqaujasuX Thanks to @myESMO #nobelprize #lymphomas
-
Senthil Damodaran MD @MDAndersonNews #ASCO20 #solidtumors #lymphomas #multiplemyeloma Phase II study of copanlisib in patients with tumors with PIK3CA mutations https://t.co/lqxw5MZoZ1 https://t.co/ruF2xbhluK